VIVIMEDLAB Latest Share Price (VIVIMEDLAB)
TODAY IN ONE LINE
With a market cap of ₹52.65 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
VIVIMEDLAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Price MomentumStock underperformed, dropping 46.2% over 1Y
- ●Sales ContractionQuarterly sales dropped 24.9% YoY
- ●Negative EarningsCompany is reporting negative EPS of ₹-17.61 (Loss Making)
- ●Low Promoter HoldingPromoters hold only 7.6%
- ●High Leverage RiskDebt-to-Equity is elevated at 8.29x
- ●Promoter SellingPromoter holding decreased by 0.20% QoQ
Latest VIVIMEDLAB News
What changed recently?
Recent events, corporate actions, and announcements.
VIVIMEDLAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for VIVIMEDLAB, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
VIVIMEDLAB technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for VIVIMEDLAB — derived from the latest tape, not yesterday's close.
VIVIMEDLAB last traded at ₹7.39 with an intraday range of ₹7.36–₹7.79 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹7.39| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 8.53 | +1.14 | +15.38% |
| R3 | 8.10 | +0.71 | +9.56% |
| R2 | 7.94 | +0.55 | +7.49% |
| R1 | 7.67 | +0.28 | +3.74% |
| PIVOT | 7.51 | 0.12 | 1.67% |
| CURRENT | 7.39 | — | — |
| S1 | 7.24 | -0.15 | -2.07% |
| S2 | 7.08 | -0.31 | -4.15% |
| S3 | 6.81 | -0.58 | -7.89% |
| S4 | 6.38 | -1.01 | -13.71% |
VIVIMEDLAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Inside opening range
VIVIMEDLAB financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for VIVIMEDLAB — consolidated or standalone — with margins, YoY growth and key ratios inline.
VIVIMEDLAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹52.65 Cr. and reported EPS of ₹-17.61.
| Metric | Apr 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 116 | 70 ▼ 39.8% |
| Sales Growth YoY %Derived | — | -39.80% |
| Other Income | 4 | 6 ▲ 44.6% |
| Total Income | 121 | 76 ▼ 36.7% |
| 60 | 74 ▲ 23.2% | |
| Gross ProfitDerived | 56 | -4 ▼ 106.7% |
| Gross Margin %Derived | 48.52% | -5.37% |
| 69 | 148 ▲ 113.9% | |
| EBITDA (Operating Profit)Derived | -13 | -151 ▼ 1102.6% |
| OPM %Derived | -10.82% | -216.24% |
| 23 | 30 ▲ 30.4% | |
| Profit Before Tax (PBT) | -31 | -175 ▼ 458.4% |
| 0 | 0 ▲ 21.2% | |
| Effective Tax %Derived | -0.36% | -0.08% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | -31 | -175 ▼ 456.8% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | -31 | -175 ▼ 456.8% |
| Net Profit Margin %Derived | -27.09% | -250.59% |
| PAT Growth YoY %Derived | — | -456.81% |
| Earnings Per Share (EPS ₹) | -3.80 | -21.15 ▼ 456.6% |
| Diluted Shares Outstanding (Cr) | 8 | 8 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | — | — |
| Total Expenses (incl. D&A & Interest) | 152 | 252 ▲ 65.5% |
| Material Cost % of RevenueDerived | 49.68% | 47.02% |
| Employee Cost % of RevenueDerived | 24.42% | 35.67% |
| Other Cost % of RevenueDerived | 34.93% | 175.20% |
| Interest Coverage (x)Derived | -11.13x | -42.54x |
| Period | Mar 2018 | Jun 2018 | Mar 2019 | Jun 2019 | Mar 2020 | Jul 2020 | Mar 2021 | Jun 2021 | Mar 2022 | Jun 2022 | Mar 2023 | May 2023 | Mar 2024 | Nov 2024 | Mar 2025 | Apr 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,186 | 1,186 ▲ 0.0% | 1,315 ▲ 10.9% | 1,315 ▲ 0.0% | 1,059 ▼ 19.5% | 1,059 ▲ 0.0% | 861 ▼ 18.6% | 861 ▲ 0.0% | 237 ▼ 72.5% | 237 ▲ 0.0% | 187 ▼ 21.2% | 187 ▲ 0.0% | 149 ▼ 20.3% | 149 ▲ 0.0% | 116 ▼ 22.0% | 116 ▲ 0.0% | 70 ▼ 39.8% | |
| Sales Growth YoY %Derived | — | — | 10.92% | 10.92% | -19.49% | — | -18.64% | — | -72.46% | -72.46% | -21.15% | — | -20.33% | — | -22.00% | — | -39.80% | |
| Other Income | 10 | 10 ▲ 0.0% | 23 ▲ 138.9% | 23 ▲ 0.0% | 8 ▼ 64.0% | 8 ▲ 0.0% | 10 ▲ 19.0% | 10 ▲ 0.0% | 1 ▼ 87.1% | 1 ▲ 0.0% | 1 ▼ 23.8% | 1 ▲ 0.0% | 10 ▲ 930.6% | 10 ▲ 0.0% | 4 ▼ 56.2% | 4 ▲ 0.0% | 6 ▲ 44.6% | |
| Total Income | 1,195 | 1,195 ▲ 0.0% | 1,338 ▲ 12.0% | 1,338 ▲ 0.0% | 1,067 ▼ 20.3% | 1,067 ▲ 0.0% | 871 ▼ 18.3% | 871 ▲ 0.0% | 239 ▼ 72.6% | 239 ▲ 0.0% | 188 ▼ 21.2% | 188 ▲ 0.0% | 159 ▼ 15.4% | 159 ▲ 0.0% | 121 ▼ 24.1% | 121 ▲ 0.0% | 76 ▼ 36.7% | |
480 | 480 ▲ 0.0% | 518 ▲ 8.1% | 518 ▲ 0.0% | 463 ▼ 10.8% | 463 ▲ 0.0% | 355 ▼ 23.4% | 355 ▲ 0.0% | 153 ▼ 56.7% | 153 ▲ 0.0% | 272 ▲ 76.9% | 272 ▲ 0.0% | 71 ▼ 73.7% | 71 ▲ 0.0% | 60 ▼ 16.3% | 60 ▲ 0.0% | 74 ▲ 23.2% | ||
| Gross ProfitDerived | 706 | 706 ▲ 0.0% | 797 ▲ 12.9% | 797 ▲ 0.0% | 596 ▼ 25.2% | 596 ▲ 0.0% | 507 ▼ 15.0% | 507 ▲ 0.0% | 84 ▼ 83.5% | 84 ▲ 0.0% | -84 ▼ 200.7% | -84 ▲ 0.0% | 78 ▲ 191.9% | 78 ▲ 0.0% | 56 ▼ 27.3% | 56 ▲ 0.0% | -4 ▼ 106.7% | |
| Gross Margin %Derived | 59.54% | 59.54% | 60.58% | 60.58% | 56.31% | 56.31% | 58.85% | 58.85% | 35.32% | 35.32% | -45.12% | -45.12% | 52.05% | 52.05% | 48.52% | 48.52% | -5.37% | |
494 | 494 ▲ 0.0% | 620 ▲ 25.4% | 620 ▲ 0.0% | 588 ▼ 5.1% | 588 ▲ 0.0% | 483 ▼ 17.8% | 483 ▲ 0.0% | 92 ▼ 81.0% | 92 ▲ 0.0% | 103 ▲ 12.0% | 103 ▲ 0.0% | 111 ▲ 7.9% | 111 ▲ 0.0% | 69 ▼ 37.8% | 69 ▲ 0.0% | 148 ▲ 113.9% | ||
| EBITDA (Operating Profit)Derived | 212 | 212 ▲ 0.0% | 177 ▼ 16.4% | 177 ▲ 0.0% | 8 ▼ 95.4% | 8 ▲ 0.0% | 24 ▲ 193.4% | 24 ▲ 0.0% | -8 ▼ 133.9% | -8 ▲ 0.0% | -187 ▼ 2223.8% | -187 ▲ 0.0% | -33 ▲ 82.2% | -33 ▲ 0.0% | -13 ▲ 62.3% | -13 ▲ 0.0% | -151 ▼ 1102.6% | |
| OPM %Derived | 17.88% | 17.88% | 13.47% | 13.47% | 0.77% | 0.77% | 2.76% | 2.76% | -3.40% | -3.40% | -100.11% | -100.11% | -22.42% | -22.42% | -10.82% | -10.82% | -216.24% | |
136 | 136 ▲ 0.0% | 134 ▼ 1.4% | 134 ▲ 0.0% | 126 ▼ 6.1% | 126 ▲ 0.0% | 109 ▼ 13.1% | 109 ▲ 0.0% | 58 ▼ 46.9% | 58 ▲ 0.0% | 144 ▲ 148.6% | 144 ▲ 0.0% | 22 ▼ 84.5% | 22 ▲ 0.0% | 23 ▲ 3.6% | 23 ▲ 0.0% | 30 ▲ 30.4% | ||
| Profit Before Tax (PBT) | 86 | 86 ▲ 0.0% | 66 ▼ 22.9% | 66 ▲ 0.0% | -109 ▼ 265.8% | -109 ▲ 0.0% | -76 ▲ 30.8% | -76 ▲ 0.0% | -65 ▲ 14.4% | -65 ▲ 0.0% | -331 ▼ 410.0% | -331 ▲ 0.0% | -46 ▲ 86.1% | -46 ▲ 0.0% | -31 ▲ 31.5% | -31 ▲ 0.0% | -175 ▼ 458.4% | |
10 | 10 ▲ 0.0% | 9 ▼ 9.8% | 9 ▲ 0.0% | -0 ▼ 104.1% | -0 ▲ 0.0% | 2 ▲ 664.5% | 2 ▲ 0.0% | 3 ▲ 38.8% | 3 ▲ 0.0% | -2 ▼ 175.2% | -2 ▲ 0.0% | -0 ▲ 82.2% | -0 ▲ 0.0% | 0 ▲ 130.0% | 0 ▲ 0.0% | 0 ▲ 21.2% | ||
| Effective Tax %Derived | 11.23% | 11.23% | 13.14% | 13.14% | 0.33% | 0.33% | -2.68% | -2.68% | -4.34% | -4.34% | 0.64% | 0.64% | 0.82% | 0.82% | -0.36% | -0.36% | -0.08% | |
| Profit/Loss from Discontinued Ops | 2 | 2 ▲ 0.0% | 57 ▲ 2996.0% | 57 ▲ 0.0% | — ▼ 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Total Profit for Period | 76 | 76 ▲ 0.0% | 57 ▼ 24.6% | 57 ▲ 0.0% | -109 ▼ 290.2% | -109 ▲ 0.0% | -78 ▲ 28.7% | -78 ▲ 0.0% | -68 ▲ 13.0% | -68 ▲ 0.0% | -329 ▼ 385.6% | -329 ▲ 0.0% | -45 ▲ 86.2% | -45 ▲ 0.0% | -31 ▲ 30.7% | -31 ▲ 0.0% | -175 ▼ 456.8% | |
| Less: Non-controlling Interests | -2 | -2 ▲ 0.0% | — ▲ 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Profit (Owner's PAT)Derived | 78 | 78 ▲ 0.0% | 57 ▼ 26.4% | 57 ▲ 0.0% | -109 ▼ 290.2% | -109 ▲ 0.0% | -78 ▲ 28.7% | -78 ▲ 0.0% | -68 ▲ 13.0% | -68 ▲ 0.0% | -329 ▼ 385.6% | -329 ▲ 0.0% | -45 ▲ 86.2% | -45 ▲ 0.0% | -31 ▲ 30.7% | -31 ▲ 0.0% | -175 ▼ 456.8% | |
| Net Profit Margin %Derived | 6.57% | 6.57% | 4.36% | 4.36% | -10.31% | -10.31% | -9.03% | -9.03% | -28.51% | -28.51% | -175.59% | -175.59% | -30.49% | -30.49% | -27.09% | -27.09% | -250.59% | |
| PAT Growth YoY %Derived | — | — | -26.40% | -26.40% | -290.21% | — | 28.70% | — | 13.04% | 13.04% | -385.64% | — | 86.17% | — | 30.69% | — | -456.81% | |
| Earnings Per Share (EPS ₹) | 9.44 | 9.44 ▲ 0.0% | 13.90 ▲ 47.2% | 13.90 ▲ 0.0% | -13.16 ▼ 194.7% | -13.16 ▲ 0.0% | -9.38 ▲ 28.7% | -9.38 ▲ 0.0% | -8.16 ▲ 13.0% | -8.16 ▲ 0.0% | -39.56 ▼ 384.8% | -39.56 ▲ 0.0% | -5.48 ▲ 86.1% | -5.48 ▲ 0.0% | -3.80 ▲ 30.7% | -3.80 ▲ 0.0% | -21.15 ▼ 456.6% | |
| Diluted Shares Outstanding (Cr) | 8 | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.5% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | -1 ▲ 0.0% | — ▲ 100.0% | — | — | — | — | — | — | — | 1 | 1 ▲ 0.0% | 1 ▲ 0.7% | 1 ▲ 0.0% | — ▼ 100.0% | — | — | |
| Total Expenses (incl. D&A & Interest) | 1,110 | 1,110 ▲ 0.0% | 1,272 ▲ 14.6% | 1,272 ▲ 0.0% | 1,177 ▼ 7.5% | 1,177 ▲ 0.0% | 947 ▼ 19.5% | 947 ▲ 0.0% | 303 ▼ 68.0% | 303 ▲ 0.0% | 519 ▲ 71.0% | 519 ▲ 0.0% | 205 ▼ 60.5% | 205 ▲ 0.0% | 152 ▼ 25.8% | 152 ▲ 0.0% | 252 ▲ 65.5% | |
| Material Cost % of RevenueDerived | 41.31% | 41.31% | 42.73% | 42.73% | 45.64% | 45.64% | 41.39% | 41.39% | 64.48% | 64.48% | 58.77% | 58.77% | 60.07% | 60.07% | 49.68% | 49.68% | 47.02% | |
| Employee Cost % of RevenueDerived | 16.68% | 16.68% | 18.38% | 18.38% | 22.04% | 22.04% | 22.71% | 22.71% | 15.27% | 15.27% | 17.46% | 17.46% | 22.91% | 22.91% | 24.42% | 24.42% | 35.67% | |
| Other Cost % of RevenueDerived | 24.98% | 24.98% | 28.73% | 28.73% | 33.51% | 33.51% | 33.37% | 33.37% | 23.45% | 23.45% | 37.54% | 37.54% | 51.56% | 51.56% | 34.93% | 34.93% | 175.20% | |
| Interest Coverage (x)Derived | 1.96x | 1.96x | 1.64x | 1.64x | -1.00x | -1.00x | -0.59x | -0.59x | -0.66x | -0.66x | -8.24x | -8.24x | -21.94x | -21.94x | -11.13x | -11.13x | -42.54x |
VIVIMEDLAB segment analysis : revenue and profit mix.
Disclosed business segments at VIVIMEDLAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
VIVIMEDLAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for VIVIMEDLAB.
Our AI distills the core fundamental drivers supporting VIVIMEDLAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 8.79. Balance sheet risk re-prices growth multiples fast.
VIVIMEDLAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — VIVIMEDLAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
VIVIMEDLAB chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for VIVIMEDLAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
VIVIMEDLAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for VIVIMEDLAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in VIVIMEDLAB stood at 74.0% of traded volume, against a 20-day average of 85.0%.
VIVIMEDLAB announcements: results, concalls, ratings, M&A.
Filings VIVIMEDLAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
VIVIMEDLAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 57 documents below.
Outcome of Board Meeting
Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Updates
Vivimed Labs Limited has informed the Exchange regarding 'COC meeting'.
General Updates
Vivimed Labs Limited has informed the Exchange about General Updates
Trading Window
Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Corporate Insolvency Resolution Process
Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process
VIVIMEDLAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue VIVIMEDLAB has declared, sequenced by announce and record date.
VIVIMEDLAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About VIVIMEDLAB: business, sector, key facts.
What VIVIMEDLAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
VIVIMEDLAB operates in the Pharmaceuticals industry under the Healthcare sector.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about VIVIMEDLAB (VIVIMEDLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of VIVIMEDLAB (VIVIMEDLAB)?
The current share price of VIVIMEDLAB (VIVIMEDLAB) is ₹7.39. Today, the stock has declined by ₹0.24 (3.15%), trading in a range of ₹7.36 to ₹7.79. The stock opened at ₹7.63 with a trading volume of 1,46,861 shares.
02What is the 52-week high and low price of VIVIMEDLAB stock?
The 52-week high price of VIVIMEDLAB (VIVIMEDLAB) is ₹20.59, while the 52-week low is ₹5.15. Currently trading at ₹7.39, the stock is 43.5% above its 52-week low and 64.11% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of VIVIMEDLAB and when is the next dividend?
VIVIMEDLAB offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹7.39, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is VIVIMEDLAB stock performing today in the market?
VIVIMEDLAB stock opened at ₹7.63 and is currently trading at ₹7.39, showing a decline of ₹0.24 (3.15%). The intraday high is ₹7.79 and low is ₹7.36. The trading volume stands at 1,46,861 shares, indicating moderate market participation today.
05What is the market capitalization of VIVIMEDLAB?
VIVIMEDLAB has a market capitalization of ₹52.65 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹7.39) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of VIVIMEDLAB?
VIVIMEDLAB has a Return on Equity (ROE) of -57.01% and Return on Capital Employed (ROCE) of -5.3%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does VIVIMEDLAB belong to?
VIVIMEDLAB operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of VIVIMEDLAB?
VIVIMEDLAB has a debt-to-equity ratio of 8.29, which measures the company's financial leverage by comparing total debt to shareholders' equity. A ratio above 2 indicates high leverage and potentially higher financial risk. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about VIVIMEDLAB (VIVIMEDLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.